%0 Journal Article
%A Hontecillas-Prieto, Lourdes
%A Garcia-Dominguez, Daniel J
%A Vaca, Diego Pascual
%A Garcia-Mejias, Rosa
%A Marcilla, David
%A Ramirez-Villar, Gema L
%A Saez, Carmen
%A de Álava, Enrique
%T Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
%D 2017
%U http://hdl.handle.net/10668/10746
%X Wilms tumour (WT) is the most common renal tumour in children. Most WT patients respond to chemotherapy, but subsets of tumours develop resistance to chemotherapeutic agents, which is a major obstacle in their successful treatment. Multidrug resistance transporters play a crucial role in the development of resistance in cancer due to the efflux of anticancer agents out of cells. The aim of this study was to explore several human multidrug resistance transporters in 46 WT and 40 non-neoplastic control tissues (normal kidney) from patients selected after chemotherapy treatment SIOP 93-01, SIOP 2001. Our data showed that the majority of the studied multidrug resistance transporters were downregulated or unchanged between tumours and control tissues. However, BCRP1, MDR3 and MRP1 were upregulated in tumours versus control tissues. MDR3 and MRP1 overexpression correlated with high-risk tumours (SIOP classification) (p = 0.0022 and p
%K MDR3
%K MRP1
%K Wilms tumours
%K blastemal stratification
%K multidrug resistance transporters
%~